Depression Research Today is a free monthly online journal that collates and summarizes the latest research about Depression, including details on clinical depression, medication, symptoms, treatment, counselling, therapy.

Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.

Otsuka T, Togo T, Sugiyama N, Uehara K, Yoshimi A, Karashima A, Shioya H, Hirayasu Y

Department of Psychiatry, Yokohama City University School of Medicine: 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.

Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT(2A) and dopamine D(2) receptors, as well as a unique agonist effects on serotonin 5-HT(1A) receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.

Published 12 February 2007 in Prog Neuropsychopharmacol Biol Psychiatry, 31(2): 564-6.
Full-text of this article is available online (may require subscription).

© 2004-2008 Depression Research Today. All Rights Reserved.